Article
Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan.
PloS one - 1 Jan 2015
Hsu Kuo-Hsuan, Ho Chao-Chi, Hsia Te-Chun, Tseng Jeng-Sen, Su Kang-Yi, Wu Ming-Fang, Chiu Kuo-Liang, Yang Tsung-Ying, Chen Kun-Chieh, Ooi Hean, Wu Tzu-Chin, Chen Hung-Jen, Chen Hsuan-Yu, Chang Chi-Sheng, Hsu Chung-Ping, Hsia Jiun-Yi, Chuang Cheng-Yen, Lin Chin-Hung, Chen Jeremy J W, Chen Kuan-Yu, Liao Wei-Yu, Shih Jin-Yuan, Yu Sung-Liang, Yu Chong-Jen, Yang Pan-Chyr, Chang Gee-Chen
Abstract excerpt
BACKGROUND: It is important to select appropriate targeted therapies for subgroups of patients with lung adenocarcinoma who have specific gene alterations. METHODS: This prospective study was a multicenter project conducted in Taiwan for assessment of lung adenocarcinoma genetic tests. Five oncogenic drivers, including EGFR, KRAS, BRAF, HER2 and EML4-ALK fusion mutations, were tested. EGFR, KRAS, BRAF and HER2...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.